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O R I G I N A L  A R T I C L E
INTRODUCTION: Diabetes mellitus is considered as a 
metabolic disorder wherein hyperglycemia occurs due 
to deficiency in production and secretion of insulin from 
pancreas or inability of body cells to respond to insulin 
secreted through pancreas, or both conditions 
simultaneously.1,2 Basic and clinical research in 
diabetes mellitus has provided profound information on 
the pathophysiological constructs of diabetic 
complications for long term outcome research.3 Oral 
and intravenous glucose tolerance tests and related 
other tests manifest the metabolic predictors for 
impaired glucose tolerance in type 2 diabetes mellitus 
(T2 DM) patients.4 Diabetes may cause damage to 
body organs including kidneys, eyes, heart, blood 
vessels, nerves etc. 5 Metabolic processes are altered 
due to hyperglycemia resulting in oxidative stress, 
production of advanced glycation end products, polyol 
pathway influx and activation of protein kinases and 
hence, damage to nerves and ultimately microvascular 
disease and neuropathy.6 Prevalence of T2DM 
increases with increase in the prevalence of obesity 
that necessitates to adopt weight centered approach 
and consider the relevance of weight in the 
management of T2DM patients.7 It has been suggested 
that quite critical cases may require glucose range to 
be maintained around 140-180mg/dL by continuous 
infusion of insulin 1 . A recent review 8 describes the 
antidiabetic drugs in the management of T2DM for 
lowering the elevated blood level of glucose.
One of the adverse complications of diabetes is 
diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
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Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
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Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
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Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
References:
1. Alam U, Asghar O, Azmi S, Malik RA. General aspects 
of diabetes mellitus. Handb Clin Neurol 2014; 
126:211-22.
2. Sohail S. Involvement of adipocytokines and related 
pathophysiological changes in patients with diabetes 
mellitus. PhD Thesis, Department of Physiology, 
University of Karachi, 2015  (PhD Degree awarded in 
2016).
3. Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin 
Iii JR, Aguilar RB, et al. A Unified Pathophysiological 
Construct of Diabetes and its Complications. Trends 
Endocrinol Metab. 2017; S1043-2760(17)30069-3.
4. Henninger J, Hammarstedt A, Rawshani A, Eliasson 
B. Metabolic predictors of impaired glucose tolerance 
and type 2 diabetes in a predisposed population--A 
prospective cohort study. BMC Endocr Disord 2015; 
;15:51.
5. Mellitus, D. Diagnosis and classification of diabetes 
mellitus. Diabetes Care 2005;  28, S37.
6. Duby JJ, Campbell RK, Setter SM, & Rasmussen KA. 
Diabetic neuropathy: an intensive review. American 
Journal of Health-System Pharmacy 2004; 61(2), 
160-173.
7. Gorgojo Martínez JJ. Relevance of weight in the 
management of patients with type 2 diabetes mellitus: 
towards an adipocentric approach to diabetes.Med Clin 
(Barc) 2016; 147 Suppl 1:8-16.
8. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, 
Chada A, Ravilla R, et al. Clinical Review of Antidiabetic 
Drugs: Implications for Type 2 Diabetes Mellitus 
Management.  Front Endocrinol (Lausanne) 2017; 8:6.
9. Juster-Switlyk K, Smith AG. Updates in diabetic 
peripheral neuropathy. F1000Res 2016;  25;5.
10. Grisold A, Callaghan BC, Feldman EL. Mediators of 
diabetic neuropathy: is hyperglycemia the only culprit? 
Curr Opin Endocrinol Diabetes Obes 2017; 
24(2):103-111.
11. Rahmani Katigari M, Ayatollahi H, Malek M, 
Kamkar Haghighi M. Fuzzy expert system for diagnosing 
diabetic neuropathy. World J Diabetes  2017; 
8(2):80-88.
12. Clarke BF, Ewing DJ, & Campbell IW. Diabetic 
autonomic neuropathy. Diabetologia 1979;  17(4), 
195-212.
13. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, 
Plater M, Ionescu-Tirgoviste C. and EURODIAB IDDM 
Complications Study Group. Prevalence of diabetic 
peripheral neuropathy and its relation to glycaemic 
control and potential risk factors: the EURODIAB IDDM 
Complications Study. Diabetologia 1996;  39(11), 
1377-1384.
14. Forrest KY, Maser RE, Pambianco G, Becker DJ, 
Orchard TJ. Hypertension as a risk factor for diabetic 
neuropathy: a prospective study. Diabetes 1997; 
46(4), 665-670.
15. Bakris GL, Sowers JR. ASH position paper: 
treatment of hypertension in patients with 
diabetes—an update. The journal of clinical 
hypertension 2008;  10(9), 707-713.
16. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei 
M, Lotfi J. Potential risk factors for diabetic neuropathy: 
a case control study. BMC neurology 2005;  5(1), 1.
17. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, 
Mielck A. Prevalence of Polyneuropathy in Pre-Diabetes 
and Diabetes Is Associated With Abdominal Obesity and 
Macroangiopathy The MONICA/KORA Augsburg Surveys 
S2 and S3. Diabetes Care 2008;  31(3), 464-469.
18. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, 
Parving HH. Albuminuria and poor glycemic control 
predict mortality in NIDDM.Diabetes  1995; 44(11), 
1303-1309.
19. Al-Ani FS, Al-Nimer MS, Ali FS. Dyslipidemia as a 
contributory factor in etiopathogenesis of diabetic 
neuropathy. Indian journal of endocrinology and 
metabolism 2011; 15(2), 110.
20. Sohail S, Hussain Z, Quratul Ain, Ashraf, SJ. Blood 
cholesterol and leptin levels in male smoking and 
non-smoking patients with diabetes mellitus. 
International Journal of Biological Research  2013; 
1(1):  15-18.
21. Sohail S, Hussain Z. Electrolyte and cholesterol 
variations in patients with diabetes mellitus. 35th All 
Pak Sc Conf, Genomics for Health and Prosperity, 
University of Karachi, 2008.
22. Hussain Z, Sohail S, Ashraf A. Blood cholesterol 
concentration in smoking and non-smoking patients 
with diabetes mellitus.  Hum Health 2007b; 3(7 & 
8):5-8
23. Hossain P, Kawar B, El Nahas M. Obesity and 
diabetes in the developing world—a growing 
challenges. New England Journal of Medicine 2007; 
356(3), 213-215.
24. Obrosova IG, Ilnytska O, Lyzogubov VV, Pavlov IA, 
Mashtalir N, Nadler JL, et al.  High-Fat Diet–Induced 
Neuropathy of Pre-Diabetes and Obesity Effects of 
“Healthy” Diet and Aldose Reductase Inhibition. 
Diabetes   2007; 56(10), 2598-2608. 
25. Mitchell BD, Hawthorne VM, Vinik AI. Cigarette 
smoking and neuropathy in diabetic patients. Diabetes 
Care 1990;   13(4), 434-437. 
26. Eliasson B. Cigarette smoking and diabetes. 
Progress in cardiovascular diseases 2003;   45(5), 
405-413.
27. Hussain Z, Sohail S, Ashraf A. Endothelial 
dysfunction, cytokines and diabetes mellitus. Hum 
Health, 2007a; 3(7 & 8):3-4.
28. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. 
Hyperlipidemia: a new therapeutic target for diabetic 
neuropathy. J Peripher Nerv Syst 2009;  14(4):257-67.
29. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler 
LM, Kitabchi AE. Hyperglycemia: an independent 
marker of in-hospital mortality in patients with 
undiagnosed diabetes. J Clin Endocrinol Metab  2002; 
87(3):978-82.
30. Estacio RO, Jeffers BW, Gifford N, Schrier RW. 
Effect of blood pressure control on diabetic 
microvascular complications in patients with 
hypertension and type 2 diabetes. Diabetes Care 2000; 
23 Suppl 2:B54-64.
31. Raskin NH, Fishman RA. Neurologic disorders in 
renal failure (second of two parts). N Engl J Med 1976; 
294(4):204-10.
32. Baumgaertel MW, Kraemer M, Berlit P. Neurologic 
complications of acute and chronic renal 
disease.Handb Clin Neurol  2014; 119:383-93.
33. Miscio G, Guastamacchia G, Brunani A, Priano L, 
Baudo S, Mauro A.  Obesity and peripheral neuropathy 
risk: a dangerous liaison.J Peripher Nerv Syst 2005; 
10(4):354-8.
34. Smith AG, Singleton JR. Obesity and hyperlipidemia 
are risk factors for early diabetic neuropathy. J Diabetes 
Complications  2013 ;27(5):436-42.
35. Kluding PM, Pasnoor M, Singh R, Jernigan S, 
Farmer K, Rucker J, et al.  The effect of exercise on 
neuropathic symptoms, nerve function, and cutaneous 
innervation in people with diabetic peripheral 
neuropathy. J Diabetes Complications 2012 
;26(5):424-9.
36. Bize R, Johnson JA, Plotnikoff RC. Physical activity 
level and health-related quality of life in the general 
adult population: a systematic review. Prev Med 2007 
;45(6):401-15.
37. Veves A, Backonja M, Malik RA. Painful diabetic 
neuropathy: epidemiology, natural history, early 
diagnosis, and treatment options. Pain Med 2008; 
9(6):660-74.
38. Benbow SJ, Wallymahmed ME, MacFarlane IA. 
Diabetic peripheral neuropathy and quality of life.QJM 
1998;  ;91(11):733-7.
39. Sohail S, Hussain Z.  Pathophysiology of ischemic 
disorders- Ischemia, adipocytokines and diabetes 
mellitus.  International Journal of Biology and 
Biotechnology   2013;  10 (2): 155-166.
40. Sohail S, Hussain Z. Influence of diet and physical 
activity in pre-diabetes. Jan 2009, 46th Annual 
Symposium, JPMC, Karachi, 2009.
V O L .  1 4  ( 2 )   A P R I L -  J U N E  2 0 1 9
diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
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Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
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compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
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significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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diabetic neuropathy9-11 that may cause multidirectional 
disturbances affecting different regions of body, nerve 
damage, disturbance in routine daily life activities and 
work, mood disorders, lack of sleep and energy and 
lack of social interaction leading to worst quality of life. 
Peripheral neuropathy increases the likelihood of foot 
complications like ulcers and amputation and Charcot 
joints, whereas damage to the autonomic functions 
including bladder problems, reproductive problems, 
gastric problems including nausea, appetite loss, 
diarrhea, constipation etc  are the result of autonomic 
neuropathy5 .Peripheral neuropathy is mainly 
responsible for morbidity and mortality in diabetic 
patients, and patients with sensorimotor neuropathy 
facing pain, numbness or tingling and loss of sensation, 
whereas the autonomic neuropathy may be responsible 
for cardiac autonomic neuropathy causing myocardial 
infarction, malignant arrhythmia, spontaneous death, 
gastro paresis, and sex related problems such as 
sterility, erectile dysfunction and bladder problems 6 . It 
has been reviewed recently. 9  
Furthermore, autonomic neuropathy increases the risk 
of mortality in diabetic patients through indirect 
mechanisms like renal failure or by direct mechanisms 
like cardiac failure or respiratory arrest 12 . 
Morphological changes in peripheral diabetic 
neuropathy are loss of myelination, proliferation of 
Schwann cells, thickening of Schwann cell basement 
membrane, damage and death of nerve root and axons 
in autonomic diabetic neuropathy sympathetic ganglia 
showing segmental demyelination and degeneration of 
axons 12 . Other changes are large sized vacuoles in 
sympathetic ganglion cells, swellings of dendrites and 
degeneration of neurons, some irregularity in 
esophageal nerves, reduction in density of myelinated 
splanchnic nerve fibers, thickening, hyperargentophilia, 
breaking and damaging of autonomic nerve fibers, 
reduction in nerve cells, greatly reduced cholinesterase 
activity in nerves of bladder wall, and marked reduction 
in number of small myelinated or unmyelinated axons 
in nerve biopsies in patients with diabetic peripheral or 
autonomic neuropathy are the important findings 12 . 
The most important risk factors of diabetic neuropathy 
are hyperglycemia, age, duration of diabetes mellitus, 
visceral obesity, height, hypertension, smoking, 
hypoinsulinemia, and dyslipidemia 2,13 . Hypertension 
and abnormalities of lipoprotein metabolism are often 
found in people with diabetes5. Hypertension has 
strong association with DSP (distal symmetric 
polyneuropathy) in people with short term duration or 
long term duration of insulin dependent diabetes 
mellitus (IDDM). Blood pressure is significantly higher 
in cases of diabetic neuropathy 14 More than 75% of 
adults with diabetes mellitus have blood pressure levels 
≥130/80 mmHg and they use antihypertensive 
medication 15 . 
Hypertension is considered an important risk factor for 
diabetic neuropathy. Hypertensives having low 
Na+K+ATPase activity and having polyol disturbances 
may lead to neurological disturbances, and those 
having ischemia may cause diabetic neuropathy also 
leading to renal disturbances 14. Hypertension may 
reduce density of myelination of peripheral nerves that 
shows that hypertension may cause peripheral diabetic 
neuropathy or may exaggerate the complications of 
peripheral diabetes neuropathy 14. 
Hyperglycemia is the main initial cause of neuropathy, 
retinopathy, nephropathy, and the patients are on high 
risk of atherosclerotic disease, heart problems, 
peripheral arterial disorders and cerebrovascular 
disease 5. Hyperglycemia and poor glycemic control are 
considered as the greatest risk factors for 
complications associated with diabetes including nerve 
damage leading to diabetic neuropathy 16 though it has 
been suggested that recent data support the role for 
components in metabolic syndrome and other risk 
factors in the development of diabetic neuropathy that 
indicates the possible novel targets beyond 
hyperglycemia in therapeutics 10. It has been found 
slightly higher in individual with IGT (impaired glucose 
tolerance) and IFG (impaired fasting glucose) than in 
individuals with NGT (normal glucose tolerance) 17. It 
has been shown that high level of urinary albumin and 
hyperglycemia may increase the mortality risk in 
patients with non-insulin dependent diabetes mellitus 
(NIDDM) 18. Dyslipidemia may contribute in the 
development of diabetic neuropathy 19.  It has been 
proposed that occurrence of diabetic neuropathy 
depends upon various risk factors including 
dyslipidemia, obesity, smoking and hypertension 13.  We 
have done several studies on the role of cholesterol in 
patients with diabetes mellitus 2,20-22. Dyslipidemia may 
leads to cardiovascular disease that is considered as 
the major cause of morbidity and mortality in diabetic 
neuropathy13.Obesity is the risk factor and complication 
in diabetes, hypertension and CVD (cardiovascular 
disease). About 18 million patients die per year due to 
CVD that relates to obesity that is considered as the 
risk factor for microvascular complications of diabetes 
such as diabetic neuropathy 23 . Defect in motor and 
sensory nerve conduction velocity, tactile allodynia and 
inability to sense alteration in temperature and 
impaired glucose tolerance were observed in obese 
mice fed with high fat diet (HFD) for inducing obesity, 
although when hyperglycemia was excluded the mice 
showed augmented sorbitol pathway activity in the 
peripheral nerve, as well as 4-hydroxynonenal adduct 
nitrotyrosine and poly(ADP-ribose) accumulation and 
12/15-lipoxygenase over expression in peripheral nerve 
and dorsal root ganglion neurons 24.   
Cigarette-smoking associated to increased 
complications of diabetic neuropathy 25 might be due to 
any of the 4000 toxic compounds and since smoking 
may cause narrowing and stiffness of arteries, reducing 
the flow of blood in body extremities, delay in wound 
healing due to ischemia, insulin resistance and 
enhancing the risk of diabetic macrovascular and 
microvascular complications causing further 
complications in diabetic nephropathy, retinopathy and 
neuropathy 26 . Hence, cessation of smoking may also 
be effective in glycemic control 2,20,26,27.
Diabetic neuropathy including acute and chronic forms 
is the most common complication associated to 
diabetes mellitus as manifested in the research work 
carried out in the pathophysiological and management 
aspects of diabetic neuropathy over the past decade9 . 
Designing the fuzzy expert system has been found quite 
helpful for specialists and general practitioners in 
detecting and diagnosing the severity of diabetic 
neuropathy for diagnosing the disease more quickly 
and improving the quality of patients’ care 11. The non 
modifiable risk factors of diabetic neuropathy (age, 
height, duration of diabetes, gender, heredity 
predisposition etc) have shown association with 
diabetic neuropathy e.g. a strong relationship between 
duration of diabetes, age and diabetic neuropathy; and 
a considerable association of gender with neuropathy; 
and male and tall diabetic patients of age more than 40 
on risk of diabetic neuropathy16. Controlling the 
modifiable risk factors has been found to be helpful in 
improving the progression of diabetic neuropathy and 
general status of patients’ health. Therefore, 
awareness should be given to patients about their life 
style interventions that may lead to better healthy life 
with fewer neuropathic complications in patients with 
diabetes mellitus.
MATERIALS AND METHODS
Research design:
This study was conducted in urban areas of Karachi. 
The prospective study was both survey and sample 
based. The sample size of study is 300 out of which 
150 are control subjects and 150 are the patients. 
Healthy individuals were included in control group and 
the diabetic patients who had 5 years duration from the 
onset of diabetes were enrolled in patients group. The 
age limit for both groups ranged between 35 to 75 
years of age. There was no reservation on gender of 
patient. The detailed questionnaire was designed by 
including the specific criteria. Aims and objectives of 
research were expressed to all study subjects. After 
taking the consent of subjects, the detailed 
questionnaire was filled out by them through interviews.
Socioeconomic status, basal body weight, family 
history of disease, and basic inquiry about diabetes 
were asked from patients. Presence of risk factors of 
diabetic neuropathy and symptoms related to diabetic 
neuropathy were marked by patients. Blood pressure 
was recorded and estimation of glycemic and lipid 
levels was done. The influence of diabetic neuropathy 
on the quality of life of subjects in the present study 
was enquired from subjects and assessed.
The level of physical activity of study subjects was 
categorized into 3 classes- low, moderate and high. 
This categorization is based on PAL (physical activity 
level).
PAL was obtained by using the following equation:
PAL =   TEE/24 hours
              BMR/BEE                  
Where, 
TEE =total energy expenditure, BMR=basal metabolic 
rate, BEE=basal energy expenditure
Total energy expenditure (TEE) = BEE x AF
AF = activity factor
Basal energy expenditure (BEE) equation:
For males: 66+13.7(wt) +5.0(ht) -6.8(age) 
For females: 655+9.6(wt) +1.8(ht)-4.7 (age)
Where, wt = basal body weight in kg, ht = body height 
in cm, age = age in years 
PHYSICAL/PHYSIOLOGICAL MEASUREMENTS:
Blood pressure: Sphygmomanometer was used to 
measure the blood pressure. Before taking recordings 
of BP the study subject was asked to relax and sit back 
calmly with ease. After 5 minutes the deflated cuff was 
wrapped around the bare upper arm and the valve on 
the rubber bulb was closed. The stethoscope was 
placed over the pulse, under the cuff. The cuff was then 
pumped up by squeezing the bulb, and as the pressure 
was released the korotkoff sounds were heard through 
the ear pieces of the stethoscope. The blood pressure 
(systolic/diastolic) was measured in terms of 
millimeters of mercury mm Hg.
BMI:  In order to determine whether the patient was 
obese or not, the body mass index (BMI) was 
calculated for every individual in the study. After 
measuring the basal body weight in kilograms and 
height in meters, BMI was calculated by using Metric 
formula.
Diagnostic tests:
Blood glucose level: Blood glucose level of study 
subjects was checked by using glucometer. First 
enquired from the patients whether they were in fasting 
state or random state, and instructed for fasting level 
requirements with their consent. A new lancet and strip 
was utilized for each subject. A cotton swab dipped in 
alcohol was taken for cleaning the index finger of study 
subjects before pricking. Subjects were instructed to 
place the drop of blood on the strip on the place of 
mark, and then to wait till reading appears on the 
screen. Readings were noted and recorded.
Lipid profile:
The lipid profile (levels of LDL, HDL and VLDL) was done 
by kit method. Blood of patients was taken and 
centrifuged. Plasma was stored in refrigerator at 
required temperature. Later the aliquots of the sample 
were used for the assessment of lipid profile.
Statistical analysis:
Statistical analysis and comparisons were carried out 
by assessing the range, percentage and mean values. 
Chi-square test was applied to check the significance 
levels of the relevant data. The p value <0.05 was 
considered significant, p value<0.01 highly significant 
and p value<0.001 very highly significant.
   
RESULTS AND DISCUSSION
Results obtained in the present study (n: 300; 50 % 
healthy control subjects and 50% diabetic patients) 
were obtained from two groups, the control group 
(38.67 % male subjects, 61.33 % female subjects) and 
the patients group (45.33% males, 54.67 females) 
(Figure 1).
Fig 1
Influence of age in the present study was analyzed for 
the subjects in the range of 35 to 75 years age. The 
range of age group was further divided into four groups 
mentioned below.
It is shown in Figure 2 that the range values of age in 
four age groups were: 
Age group I:  (36-45 years; 16.67% patients of total 
patients, 47.33% controls of total controls)
Age group II: (46-55 years; 42.67% patients of total 
patients, 23.33% controls of total controls)
Age group III:(56-65 years; 28.67% patients of total 
patients, 19.33% controls of total controls)
Age group IV:(66-75 years; 12.00% patients of total 
patients, 10.00% controls of total controls) 
Fig 2 
Figure 3 shows that diabetes and other complications 
associated to diabetic neuropathy had strong relation 
with inheritance. The patients had higher family history 
of disease. 82.67% of patients and 32.67 % of 
controls had family history of diabetes. 60.67% patents 
and 25.33% controls reported family history of 
hypertension. Family history of kidney diseases was 
reported by 26% of patients and 6% of controls. It was 
found that 48% patients and 4.67% of controls had 
family history of CVD. 
Fig 3  
Figure 4 shows that the study subjects had a variety of 
chronic diseases. Zero % patients and 0% controls had 
diabetes type 1. Diabetes type 2 was reported by 100% 
of patients and 0% of controls, 62% patients and 
0.67% of controls had dyslipidemia. Hypertension was 
observed in 72% of patients and 0% of controls. The 
prevalence of CVD was 0% in controls and 10% in 
patients. The lung disorders were 2.67% in patients 
and 0% in controls. Zero % of controls and 5.33% of 
patients specifically had kidney disorders.
Fig 4 
It was observed that the level of physical activity was 
poor in patients as compared to controls. 66.67% 
patients and 38% of controls had low level of physical 
activity. 27.33% patients and 42.67% controls had 
moderate level of physical activity. High level of physical 
activity was observed in 19.33% of controls and only 
6% of patients (Figure 5).
Fig 5 
The unawareness and carelessness were observed high 
in population. Majority of patients were unaware of the 
importance of checking blood sugar level. 24.67% 
patients reported that they check their blood sugar 
once a week. Twice in a week was reported by 8.67% 
patients. 6.67% patients told that they check their 
sugar level thrice a week. 3.33% patients reported that 
they check their sugar level 4 to 5 times a week. 2.67% 
were those checking six times a week. 8.67 % majority 
of those who were on insulin reported that they check 
their blood sugar level daily. 42% patients are those 
who reported that they do not check their blood sugar 
in a week (Figure 6).
Fig 6  
Figure 7 shows that the prevalence of all risk factors 
such as tobacco addiction, heavy alcohol consumption, 
hypertension, hyperglycemia, obesity, kidney disorders 
was significantly higher (p<0.05) in patients group as 
compare to controls group. The prevalence of tobacco 
addiction was observed 0% in control and 32% in 
patients group. Alcohol addiction was obtained in very 
few percent of population because of religious terms 
and conditions but in patient group 3.33 % of alcohol 
addiction was observed while in control it was observed 
in 0% of study subjects. The prevalence of renal 
disease was observed 0% in control group and 10% in 
patient group. Hyperglycemia was found markedly 
higher in patient group which was 80% whereas in 
control group its prevalence was 0%. Hypertension was 
the 2nd highest risk factor which was observed to be 
76.67% in patient group and 0% in controls. 
Dyslipidemia was found in higher percentage in patient 
group about 60% and 0% in control group. Obesity was 
observed 60% in patient group which is quite high than 
in control group which had 3.33% prevalence of 
obesity.
Fig 7 
Table 1 shows the prevalence of symptoms in study 
subjects. It was observed that the prevalence of the 
observed symptoms were significantly higher (p<0.05) 
in patient group as compared to control group. 
TABLE 1
Figure 8 shows the level of severity of diabetic 
neuropathy in patient group. 13.33% of patients were 
reported little severe level of diabetic neuropathy, 
30.67% were reported moderate level of severity in 
diabetic neuropathy and 56% of patients were claimed 
high level of severity.
Fig 8
Diabetic neuropathy was observed to become worsen 
with time so large number of patients claimed that the 
complications and symptoms related to diabetic 
neuropathy were going to exaggerate with time (Figure 
9).
Fig 9
The 20% subjects reported that diabetic neuropathy put 
little impact on their life, 32% reported that diabetic 
neuropathy added moderate level of complications on 
their life and 48% reported that diabetic neuropathy 
harshly put high level of bad impact on their life (Figure 
10).
Fig 10 
In the present study, it was observed that diabetic 
neuropathy has direct relationship with duration of 
diabetes since 94% patients showed long duration of 
diabetes at least for more than 5 years. Detailed 
studies about the insights for the diagnostic and 
management aspects 9-11 are helpful in interpreting 
the findings. In accordance to present study smoking 
and alcohol addiction, hypertension, hyperglycemia, 
kidney disease, dyslipidemia and obesity are the 
important risk factors of diabetic neuropathy. It was 
revealed 12 that the significant correlation was present 
between prevalence of diabetic neuropathy with 
smoking (p<0.001), dyslipidemia (p<0.001). The 
significant correlation existed between prevalence of 
symptoms of diabetic neuropathy in patient who had 
tobacco addiction. The prevalence of tobacco addiction 
is significantly higher in patients in comparison of 
control (p<0.05). In present study the prevalence of 
smoking is 32% patients and 0% in controls. The 
prevalence of dyslipidemia was extensively studied in 
one study in patients with diabetic neuropathy 28 . In 
present study the dyslipidemia is significantly higher in 
patients (p<0.05) than control group. Dyslipidemia 
was observed 0.67% in controls and 60% in patients. It 
has been concluded that the hyperglycemia is 
responsible for neural and vascular damage. In another 
study, 38% diabetic patients showed hyperglycemia 29 
. In present study 80% patients had hyperglycemia. The 
prevalence of hyperglycemia is significantly higher in 
patients than control (p<0.05), therefore according to 
present study the hyperglycemia is the major risk factor 
for complications of diabetic neuropathy. It was found 
14 that long duration of diabetes, uncontrolled blood 
pressure, hypertension, hyperglycemia and smoking 
were all independent risk factors of the likelihood of 
distal symmetric polyneuropathy (all p < 0.0001, 
except for smoking for which p = 0.03). The 
hypertension was noted to have relationship with 
vascular disease in diabetes 30 . The blood pressure was 
higher in patients than control group. Similar results for 
the role of blood pressure in patients with diabetes 
mellitus were obtained in another study2 . In our current 
study, it is also evident that hypertension that was 
76.67% in patient group and 0% in control group ; and 
there was significant (p<0.05) relationship between 
hypertension and diabetic neuropathy.  Electrolyte 
changes in patients with diabetes mellitus obtained in 
our previous work 2,21 is quite interesting and provides 
evidence of the influence of blood pressure in diabetes 
mellitus. Neuropathy may occur in at least 65% of 
patients who are about to begin dialysis for chronic 
renal failure 31 . In the present study the prevalence of 
kidney disease is significantly higher (p<0.05) in 
patients as compared to control group. Prevalence of 
neuropathy in patients with renal disease was 
evaluated that provided better idea 32 . Alcohol 
consumption may be responsible for absence of leg 
reflexes and autonomic dysfunction but there was no 
significant correlation between of alcohol consumption 
and neuropathy 13 . In our study the prevalence of 
alcohol consumption was 3.33% in patient group and 
0% in control group. It was found that the obese 
patients showed significantly decreased compound 
muscle action potential amplitude of tibial and peroneal 
nerves and decreased sensory action potential 
amplitude of all nerves33 . Most of the sensory 
thresholds were altered in obese patients. Insulin 
serum levels were significantly increased in obese 
patients. It was also observed that high level of 
triglycerides and BMI higher than 30 were risk factors 
for progression of complication related to diabetic 
neuropathy 34 . These factors enhanced the risk of 
neuropathy (p<0.05). It was observed that obesity and 
triglycerides were related to loss of small unmyelinated 
axons. These findings indicated that obesity and 
hyperglycemia significantly increase risk for peripheral 
neuropathy, independent of glucose control. In our 
study it was observed that the prevalence of obesity 
was significantly higher in patient with diabetic 
neuropathy than to control group (p>0.05).The 
prevalence of obesity is 60% in patient group and 
3.33% in control group. The exercise intervention had 
been associated with improved neuropathic symptoms, 
nerve function, and cutaneous innervation in patients 
with peripheral diabetic neuropathy 35 . They observed 
the significant reduction in pain (− 18.1 ± 35.5 mm 
on a 100 mm scale, p = .05), neuropathic symptoms 
(− 1.24 ± 1.8 on mnsi, p = .01), and increased intra 
epidermal nerve fiber branching (+ 0.11 ± 0.15 
branch nodes/fiber, p = .008) in patients who did 
aerobics and other strenuous exercise.  There was 
positive association between physical activity and 
health-related quality of life 36 . In present study, there 
was highly significant low level of physical activity 
observed in patient group in comparison with control 
group (p>0.0001). Our previous studies also point out 
the involvement of physical activity and diet in diabetes 
mellitus 2,21 .It was investigated that diabetic 
neuropathy put significant impact on the quality of life 
and diabetic neuropathy was considered as financial 
burden 37 . In our study the higher number of patients 
complained for symptoms of peripheral neuropathy 
such as muscle weakness especially in legs 88%, bone 
and joint pain 79%, numbness and tingling 76% and 
sharp pain and cramps 72% (Table 1). The quality of life 
(QOL) was found to be badly affected by diabetic 
neuropathy 38 that was assessed by the QOL using the 
Nottingham health profile (NHP). The NHP was based 
on six domains assessing energy, sleep, pain, physical 
mobility, emotional reactions and social isolation. The 
diabetic patients who had neuropathic symptoms had 
significantly higher scores (impaired QOL) in 5/6 in that 
assessment of NHP domains than the diabetic patients 
who had no symptoms of neuropathy (p < 0.01) or 
than who were non-diabetic (p < 0.001) controls. The 
diabetic patients with neuropathy had emotional 
distress, lack of energy, pain, physical mobility and 
sleep disturbance. In the current study little impact of 
neuropathy was reported by 13.33% of patients, 
moderate impact of neuropathy was observed in 
30.67% of patients while high impact of neuropathy on 
quality of life was reported as 56% of patients. Our 
previous work on endothelial dysfunction, cytokines and 
diabetes mellitus 2,22,27,39 specially leptin 
2,20,21,39 and ischemia and adipokines 2,20 
emphasizes for studying the involvement of cytokines 
and ischemia in relation to various risk factors in 
patients with diabetes mellitus and diabetic patients 
with diabetic neuropathy.  Hence, to clarify the 
pathobiological aspects in diabetic neuropathy requires 
further studies considering the important and recent 
investigations 1-4,7-11,40 to understand the 
pathophysiological changes occurring in diabetic/ 
diabetic neuropathic patients with various risk factors.
CONCLUSIONS
The prevalence of diabetic mellitus type 2 has 
increased much in our population and complications 
associated with diabetes are also increasing day by day. 
One of the major complications of diabetes is diabetic 
neuropathy. The prevalence of diabetic neuropathy is 
quite high in our population and it is is increasing 
gradually because of unawareness of risk factors that 
contribute in adding complications in diabetic patients. 
Therefore, the patients could become able to 
successfully prevent and delay the incidence of 
neuropathy by proper care, healthy diet, increasing 
level of physical activity and controlling the risk factors.
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